Company profile MBRX

Moleculin Biotech Inc
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml.... we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors. Show More
Quarter analysis & expected interestLast update: February 08 2024 01:09:50.

After 38 days of this quarter the interest is at 6.0. Based on that we can calculate that during remaining 53 days it will total up to 14.0.
Moleculin Biotech expected interest is significantly lower compared to previous quarter (-65.0%) and same quarter last year (-72.5%).

YearQ1Q2Q3Q4
20199
99
1000.0% QoQ
22
-77.8% QoQ
0
-100.0% QoQ
2020 106
1077.8% YoY inf% QoQ
372
275.8% YoY 250.9% QoQ
111
404.5% YoY -70.2% QoQ
33
inf% YoY -70.3% QoQ
2021 147
38.7% YoY 345.5% QoQ
61
-83.6% YoY -58.5% QoQ
6
-94.6% YoY -90.2% QoQ
15
-54.5% YoY 150.0% QoQ
2022 12
-91.8% YoY -20.0% QoQ
8
-86.9% YoY -33.3% QoQ
23
283.3% YoY 187.5% QoQ
24
60.0% YoY 4.3% QoQ
2023 51
325.0% YoY 112.5% QoQ
32
300.0% YoY -37.3% QoQ
34
47.8% YoY 6.2% QoQ
40
66.7% YoY 17.6% QoQ
2024 6
-88.2% YoY -85.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Moleculin Biotech search interestLast update: February 08 2024 01:09:50.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 01:09:51.

The average 5 years interest of Moleculin Biotech was 4.64 per week.
The last year interest of Moleculin Biotech compared to the last 5 years has changed by -37.5%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 8.61%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Annamycin for leukemia to provide analysis

Correlation between past revenue and Annamycin for leukemia search interest

There is not enough data for Annamycin for leukemia to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Annamycin for leukemia to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for WP1066 brain tumors to provide analysis

Correlation between past revenue and WP1066 brain tumors search interest

There is not enough data for WP1066 brain tumors to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for WP1066 brain tumors to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for WP1220 cutaneous T-cell lymphoma to provide analysis

Correlation between past revenue and WP1220 cutaneous T-cell lymphoma search interest

There is not enough data for WP1220 cutaneous T-cell lymphoma to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for WP1220 cutaneous T-cell lymphoma to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for WP1122 glioblastoma multiforme to provide analysis

Correlation between past revenue and WP1122 glioblastoma multiforme search interest

There is not enough data for WP1122 glioblastoma multiforme to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for WP1122 glioblastoma multiforme to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Moleculin Biotech stock. to provide analysis

Correlation between past revenue and Moleculin Biotech stock. search interest

There is not enough data for Moleculin Biotech stock. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Moleculin Biotech stock. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for MBRX
Earnings date: 2024-03-20 After close
Company name: Moleculin Biotech Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-20T05:12:00-07:00

GlobeNewswire
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

2026-10-16T06:20:00-07:00

GlobeNewswire
Moleculin Announces Reverse Stock Split

2026-10-07T05:45:00-07:00

GlobeNewswire
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

2026-09-14T05:35:00-07:00

GlobeNewswire
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

2026-08-28T11:10:23.425472654Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

2026-08-27T06:01:00-07:00

GlobeNewswire
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

2026-08-27T09:01:00-04:00

AccessWire
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs

2026-08-14T05:30:00-07:00

GlobeNewswire
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

2026-07-31T07:12:00-07:00

GlobeNewswire
Moleculin Announces Pricing of $9.3 Million Public Offering

2026-07-31T05:10:00-07:00

GlobeNewswire
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

2026-07-06T12:00:00-04:00

Earnings Call Transcripts
MBRX_WTM_P3Data_07.06.26 - MBRX

2026-07-06T12:00:00-04:00

Earnings Call Transcripts
MBRX_Why One Cycle Matters_07.06.26 - JTC TEAM

2026-07-06T12:00:00-04:00

Earnings Call Transcripts
MBRX_Competitive Landscape - JTC TEAM

2026-07-06T05:33:00-07:00

GlobeNewswire
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

2026-07-02T14:14:00-04:00

Earnings Call Transcripts
MBRX_Venetoclax Patients - JTC TEAM